Catheter Precision (VTAK) Common Equity (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Common Equity data on file, last reported at $9.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $9.6 million, up 20.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (up 20.88% YoY), and the FY2025 annual result was $6.7 million, down 43.43% from the prior year.
• Common Equity grew to $9.6 million in Q1 2026 per VTAK's latest filing, from $6.7 million in the prior quarter.
• Over five years, Common Equity peaked at $35.9 million in Q1 2023 and troughed at $6.4 million in Q3 2025.
• A 5-year average of $14.5 million and a median of $12.5 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity jumped 142.99% in 2023, then sank 57.27% in 2025.
• A 5-year view of Common Equity shows it stood at $9.3 million in 2022, then surged by 128.87% to $21.2 million in 2023, then tumbled by 44.52% to $11.8 million in 2024, then slumped by 43.43% to $6.7 million in 2025, then surged by 43.87% to $9.6 million in 2026.
• Business Quant data shows VTAK's Common Equity at $9.6 million in Q1 2026, $6.7 million in Q4 2025, and $6.4 million in Q3 2025.